Product Images Fulvestrant

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 18 images provide visual information about the product associated with Fulvestrant NDC 68462-317 by Glenmark Pharmaceuticals Inc., Usa, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

CTN

CTN

Figure1

Figure1

Figure10

Figure10

Figure11

Figure11

The text describes the censored observations of a study comparing the effects of Fulvestrant plus Abemacicib versus Fulvestrant plus Placebo. The study included 446 participants in the Fulvestrant plus Abemaciclib group and 223 participants in the Fulvestrant plus Placebo group. Time is also mentioned in months.*

Figure12

Figure12

The provided text represents a table that displays statistical data collected for two different treatments (Fulvestrant plus Abemaciclib and Fulvestrant plus Placebo) over a period of 57 months. The number of patients enrolled in each treatment is included in this table. Data is also provided for the number of censored observations, the number of patients at risk, and the time that has elapsed in months in the study for each treatment.*

Figure13

Figure13

Figure14

Figure14

Figure9

Figure9

figure-2 - figure 2

figure-2 - figure 2

figure-3 - figure 3

figure-3 - figure 3

figure-4 - figure 4

figure-4 - figure 4

figure-5 - figure 5

figure-5 - figure 5

figure-6 - figure 6

figure-6 - figure 6

The text shows a chart illustrating the Progression Free Survival of patients receiving Fulvestrant 250mg and Fulvestrant 500mg, in which the proportion of patients progress-free is represented against time. The chart indicates the number of patients at risk for each treatment at different time intervals.*

figure-8 - figure 8

figure-8 - figure 8

figure7 - figure7

figure7 - figure7

The text describes a graph showing the proportion of patients alive over time, with tick marks indicating censored observations. The graph compares two treatments, Fulvestrant 500mg and Fulvestrant 250mg, and shows the number of patients "at risk" for each treatment at various time points. The text notes that the results were not statistically significant as no adjustments were made for multiplicity.*

image 01

image 01

logo - logo

logo - logo

structure - structure

structure - structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.